News & Updates

Show Multimedia Only

Age drives retreatment in patients treated with teprotumumab

16 Jan 2025

Repeat treatment is not uncommon among patients who received a full course of teprotumumab therapy for thyroid eye disease (TED), and the sole predictor of retreatment is age.

Age drives retreatment in patients treated with teprotumumab

16 Jan 2025

Intravitreal anti-VEGF therapy tied to serious adverse drug reactions

16 Jan 2025

Adverse drug reactions (ADRs) appear to be significantly increased following intravitreal anti-VEGF treatment, particularly cardiovascular and cerebrovascular events, according to a recent study.

Intravitreal anti-VEGF therapy tied to serious adverse drug reactions

16 Jan 2025

Glaucoma worsens faster in longer eyes

15 Jan 2025

Glaucoma tends to be more severe and to progress quicker in the longer eye when there is an axial length difference of >1.0 mm, reveals a study.

Glaucoma worsens faster in longer eyes

15 Jan 2025

Lipid-lowering drugs for AMD? Genotyping may guide treatment

04 Jan 2025 by

Lipid-lowering drugs appear to exert a beneficial effect on age-related macular degeneration (AMD) but only in the presence of the rs1061170 genetic variant located in the CFH gene, as shown in a Singapore study.

Lipid-lowering drugs for AMD? Genotyping may guide treatment

04 Jan 2025

Physically active children have healthier retinal vasculature

14 Dec 2024 by

The Hong Kong Children Eye Study in nearly 12,000 local children aged 6–8 years shows that increased physical activity is associated with healthier retinal microvasculature.

Physically active children have healthier retinal vasculature

14 Dec 2024

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

13 Dec 2024 by

In patients with type 2 diabetes (T2D), treatment with empagliflozin has a null effect on the risk of nonproliferative diabetic retinopathy (NPDR) compared with a DPP-4 inhibitor but may confer protection against DR progression, according to a study.

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

13 Dec 2024

Baseline IOP predicts treatment response for SLT, PGA drops

11 Dec 2024 by

Primary treatment with either selective laser trabeculoplasty (SLT) or prostaglandin analog (PGA) drops for ocular hypertension and open-angle glaucoma results in a decrease in intraocular pressure (IOP), and this benefit is greater with higher baseline IOP, a study has shown.

Baseline IOP predicts treatment response for SLT, PGA drops

11 Dec 2024

Risk of depression high in retinitis pigmentosa

24 Nov 2024

Retinitis pigmentosa may predispose patients to depression, as reported in a retrospective study.

Risk of depression high in retinitis pigmentosa

24 Nov 2024

RLRL therapy beneficial in children with high myopia

23 Nov 2024

Treatment with repeated low-level red light (RLRL) shows greater efficacy among children and adolescents with high myopia, resulting in substantial axial shortening, reports a study.

RLRL therapy beneficial in children with high myopia

23 Nov 2024

$Visual impairment is mainly caused by cataract, glaucoma and diabetic retinopathy in older persons and untreated refractive e$

Visual impairment is mainly caused by cataract, glaucoma and diabetic retinopathy in older persons and untreated refractive error in children.

18 Nov 2024 by

A study in University of Malaya Medical Centre (UMMC) underscored the need for early detection of visual impairment in preventing blindness in every age group.

Visual impairment is mainly caused by cataract, glaucoma and diabetic retinopathy in older persons and untreated refractive error in children.

18 Nov 2024

News & Updates

Showing Ophthalmology articles

Showing

Specialty:

Age drives retreatment in patients treated with teprotumumab

Age drives retreatment in patients treated with teprotumumab

Intravitreal anti-VEGF therapy tied to serious adverse drug reactions

Intravitreal anti-VEGF therapy tied to serious adverse drug reactions

Glaucoma worsens faster in longer eyes

Glaucoma worsens faster in longer eyes

Lipid-lowering drugs for AMD? Genotyping may guide treatment

Lipid-lowering drugs for AMD? Genotyping may guide treatment

Physically active children have healthier retinal vasculature

Physically active children have healthier retinal vasculature

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

Diabetic retinopathy progression lower with empagliflozin vs DPP-4 inhibitor

Baseline IOP predicts treatment response for SLT, PGA drops

Baseline IOP predicts treatment response for SLT, PGA drops

Risk of depression high in retinitis pigmentosa

Risk of depression high in retinitis pigmentosa

RLRL therapy beneficial in children with high myopia

RLRL therapy beneficial in children with high myopia

Visual impairment is mainly caused by cataract, glaucoma and diabetic retinopathy in older persons and untreated refractive error in children.

Visual impairment is mainly caused by cataract, glaucoma and diabetic retinopathy in older persons and untreated refractive error in children.